BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Practice & Research Clinical Gastroenterology 2017;31:281-9. [DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 2018;67:945-52. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 25.5] [Reference Citation Analysis]
2 Cornberg M, Manns MP. Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA? Nat Rev Gastroenterol Hepatol 2018;15:195-6. [PMID: 29382951 DOI: 10.1038/nrgastro.2017.185] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
3 Choi GH, Kim G, Choi J, Han S, Lim Y. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [DOI: 10.1111/apt.15311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
4 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Reference Citation Analysis]
5 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Jackson K, Locarnini S, Gish R. Diagnostics of Hepatitis B Virus: Standard of Care and Investigational. Clin Liver Dis (Hoboken) 2018;12:5-11. [PMID: 30988902 DOI: 10.1002/cld.729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
7 Wang ML, Liao J, Ye F, Tao YC, Wu DB, He M, Tang H, Chen EQ. Distribution and factors associated with serum HBV pregenomic RNA levels in Chinese chronic hepatitis B patients. J Med Virol 2021;93:3688-96. [PMID: 32949174 DOI: 10.1002/jmv.26529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H, Laveille C, Radreau-Pierini P, Darteil R, Vonderscher J, Scalfaro P, Tangkijvanich P, Flisiak R, Reesink H. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study. J Viral Hepat 2021;28:1690-8. [PMID: 34467593 DOI: 10.1111/jvh.13608] [Reference Citation Analysis]
10 Zhang S, Wang F, Zhang Z. Current advances in the elimination of hepatitis B in China by 2030. Front Med. 2017;11:490-501. [PMID: 29170919 DOI: 10.1007/s11684-017-0598-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
11 Svicher V, Salpini R, Malagnino V, Piermatteo L, Alkhatib M, Cerva C, Sarmati L. New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. Viruses 2019;11:E783. [PMID: 31450680 DOI: 10.3390/v11090783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
12 Liao H, Li L, Zheng WV, Zou J, Yu G, Si L, Ge F, Zhou T, Ji D, Chen X, Xu D, Cheng G, Liu Y, Chen J, Colangelo L. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/4133283] [Reference Citation Analysis]
13 Popa GL, Popa MI. Oxidative Stress in Chronic Hepatitis B—An Update. Microorganisms 2022;10:1265. [DOI: 10.3390/microorganisms10071265] [Reference Citation Analysis]
14 Dusheiko G. Current and future directions of management of hepatitis B: steps toward a cure. Future Virology 2018;13:189-209. [DOI: 10.2217/fvl-2017-0103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Fontana RJ, Avigan MI, Janssen HLA, Regev A, Mishra P, Gaggar A, Brown N, Wat C, Mendez P, Anderson RT, Given B, Miller V, Beumont M. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hepat 2020;27:96-109. [PMID: 31828894 DOI: 10.1111/jvh.13223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V. Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus. Gastroenterology 2019;156:529-533.e4. [DOI: 10.1053/j.gastro.2018.11.062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
17 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]